Back to News
Market Impact: 0.35
TransMedics Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsCompany Fundamentals
TransMedics reported third-quarter 2026 revenue of $203.0 million, up 41% from $143.8 million in the third quarter of 2025. Product revenue increased 29% to $113.4 million; the provided article text cuts off before giving the remaining results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
TMDX0.55
More News
- Election Fallout and Earnings Shake Up Wall Street
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise